Market Place
Sourcing Support
US FDA approves French drugmaker Ipsen`s rare bone disorder drug
17 Aug 2023 //
REUTERS
Ipsen says EC rejects marketing authorization for bone disorder drug
19 Jul 2023 //
REUTERS
FDA adcomm votes in favor of Ipsen`s fibrodysplasia drug
29 Jun 2023 //
ENDPTS
Ipsen announces +ve outcome of FDA Advisory Committee on investig. palovarotene
28 Jun 2023 //
GLOBENEWSWIRE
FDA reviewers on Ipsen`s potential ultra-rare disease drug
27 Jun 2023 //
ENDPTS
Ipsen receives CHMP negative opinion, following re-examination of FOP treatment
26 May 2023 //
GLOBENEWSWIRE
Ipsen’s rare disease drug palovarotene knocked back in EU
28 Jan 2023 //
BUSINESSWIRE
Ipsen receives Complete Response Letter for palovarotene
24 Dec 2022 //
PRESS RELEASE
Ipsen faces yet another delay for rare disease drug in US
26 Oct 2022 //
PHARMAPHORUM
FDA plans Halloween adcomm for Ipsen’s second chance at rare disease drug
22 Aug 2022 //
ENDPTS
Ipsen Announces U.S. FDA Priority Review for palovarotene NDA
28 Jun 2022 //
BUSINESSWIRE
Health Canada Approves Ipsen’s Sohonos for Fibrodysplasia Ossificans Progressiva
24 Jan 2022 //
BUSINESSWIRE
Ipsen Announces Withdrawal of Palovarotene NDA
13 Aug 2021 //
BUSINESSWIRE
A $1B-plus drug stumbles into another big PhIII setback
28 Jan 2020 //
END PTS
FDA hits Ipsen`s $1B drug with clinical hold over safety signal
07 Dec 2019 //
FIERCE BIOTECH
Ipsen bags Blueprint drug to move deeper into ultra-rare disease
16 Oct 2019 //
FIERCE BIOTECH
Ipsen & Blueprint Medicines Announce Excl. Global License Agreement for BLU-782
16 Oct 2019 //
BUSINESSWIRE
Ipsen buys rare disease group Clementia in $1.3bn deal
26 Feb 2019 //
PRESS RELEASE
With Clear FDA Path, Clementia Raises $70.2M
31 Oct 2018 //
BIOCENTURY
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.